| Verf.angabe: | Georgios Tsivgoulis, MD, Duncan Wilson, MD, Aristeidis H. Katsanos, MD, João Sargento‐Freitas, MD, Cláudia Marques‐Matos, MD, Elsa Azevedo, MD, PhD, Tomohide Adachi, MD, Christian von der Brelie, MD, Yoshifusa Aizawa, MD, Hiroshi Abe, MD, Hirofumi Tomita, MD, Ken Okumura, MD, Joji Hagii, MD, David J. Seiffge, MD, Vasileios-Arsenios Lioutas, MD, Christopher Traenka, MD, Panayiotis Varelas, MD, Ghazala Basir, MBBS, FCPS, Christos Krogias, MD, Jan C. Purrucker, MD, Vijay K. Sharma, MD, Timolaos Rizos, MD, Robert Mikulik, MD, PhD, Oluwaseun A. Sobowale, MD, Kristian Barlinn, MD, Hanne Sallinen, MD, Nitin Goyal, MD, Shin-Joe Yeh, MD, Theodore Karapanayiotides, MD, Teddy Y. Wu, MD, PhD, Konstantinos Vadikolias, MD, Marc Ferrigno, MD, Georgios Hadjigeorgiou, MD, Rik Houben, MD, Sotirios Giannopoulos, MD, Floris H. B. M. Schreuder, MD, Jason J. Chang, MD, Luke A. Perry, BSc, Maximilian Mehdorn, MD, João-Pedro Marto, MD, João Pinho, MD, Jun Tanaka, MD, Marion Boulanger, MD, Rustam Al-Shahi Salman, FRCP Edin, Hans R. Jäger, MD, FRCR, Clare Shakeshaft, MSc, Yusuke Yakushiji, MD, Philip M.C. Choi, MBChB, FRACP, Julie Staals, MD, PhD,Charlotte Cordonnier, MD, Jiann-Shing Jeng, MD, PhD, Roland Veltkamp, MD, Dar Dowlatshahi, MD, PhD, Stefan T. Engelter, MD, Adrian R. Parry‐Jones, MD, Atte Meretoja, MD, PhD, MSc, Panayiotis D. Mitsias, MD, Andrei V. Alexandrov, MD, Gareth Ambler, PhD, David J. Werring, MD |
|---|
| Abstract: | Objective Whether intracerebral hemorrhage (ICH) associated with non-vitamin K antagonist oral anticoagulants (NOAC-ICH) has a better outcome compared to ICH associated with vitamin K antagonists (VKA-ICH) is uncertain. Methods We performed a systematic review and individual patient data meta-analysis of cohort studies comparing clinical and radiological outcomes between NOAC-ICH and VKA-ICH patients. The primary outcome measure was 30-day all-cause mortality. All outcomes were assessed in multivariate regression analyses adjusted for age, sex, ICH location, and intraventricular hemorrhage extension. Results We included 7 eligible studies comprising 219 NOAC-ICH and 831 VKA-ICH patients (mean age = 77 years, 52.5% females). The 30-day mortality was similar between NOAC-ICH and VKA-ICH (24.3% vs 26.5%; hazard ratio = 0.94, 95% confidence interval [CI] = 0.67-1.31). However, in multivariate analyses adjusting for potential confounders, NOAC-ICH was associated with lower admission National Institutes of Health Stroke Scale (NIHSS) score (linear regression coefficient = −2.83, 95% CI = −5.28 to −0.38), lower likelihood of severe stroke (NIHSS > 10 points) on admission (odds ratio [OR] = 0.50, 95% CI = 0.30-0.84), and smaller baseline hematoma volume (linear regression coefficient = −0.24, 95% CI = −0.47 to −0.16). The two groups did not differ in the likelihood of baseline hematoma volume < 30cm3 (OR = 1.14, 95% CI = 0.81-1.62), hematoma expansion (OR = 0.97, 95% CI = 0.63-1.48), in-hospital mortality (OR = 0.73, 95% CI = 0.49-1.11), functional status at discharge (common OR = 0.78, 95% CI = 0.57-1.07), or functional status at 3 months (common OR = 1.03, 95% CI = 0.75-1.43). Interpretation Although functional outcome at discharge, 1 month, or 3 months was comparable after NOAC-ICH and VKA-ICH, patients with NOAC-ICH had smaller baseline hematoma volumes and less severe acute stroke syndromes. Ann Neurol 2018;84:702-712 |
|---|
Online-Ressource
